Ectonucleotidases in ischemic heart disease

外切核苷酸酶在缺血性心脏病中的作用

基本信息

  • 批准号:
    10213112
  • 负责人:
  • 金额:
    $ 38.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-07-14 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

More than 1 million people in the United States suffer a myocardial infarction (MI) each year. Myocardial infarction (MI) evokes an intense inflammatory response. Paracrine and autocrine released extracellular ATP (eATP), signaling through purinergic P2 receptors (P2X and P2Y), is a potent modulator of macrophage and fibroblast function. Extracellular ATP is hydrolyzed by the transmembrane protein Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) to yield adenosine monophosphate (AMP), thereby halting pro-inflammatory ATP-mediated signaling. This goal of the project is to define the role of the macrophage and fibroblast- expressed CD39 on post-MI cardiac repair. To accomplish this goal we propose the following: Aim 1: To determine whether CD39 up-regulation is a protective mechanism that constrains autocrine ATP-driven inflammation, preventing exaggerated macrophage responses, and protecting from adverse post-MI fibrosis we will: 1) determine how CD39 activity impacts TLR-4-dependent and IL-4-dependent macrophage functions in vitro, 2) determine the impact of CD39 activity on the in vivo macrophage phenotypic transition from inflammatory to profibrotic functions during post-MI repair, and 3) Determine the role of macrophage CD39 on post-MI repair fibrosis in vivo. Aim 2: To dissect the purinergic pathways involved in CD39-mediated restraint of TGF-β1 activation of cardiac fibroblasts and determine the role of CD39 upregulation in modulating fibroblast function and regulating cardiac repair following MI we will 1) determine the downstream targets through which CD39 attenuates TGF-β1-mediated cardiac fibroblast inflammatory and fibrotic responses, 2) determine the impact of CD39 on the in vivo cardiac fibroblast phenotype during cardiac repair and 3) determine the impact of fibroblast CD39 on in vivo extracellular matrix remodeling during post-MI repair. Secondary Aim: To determine the impact of CD39 expression extracellular matrix remodeling we will use state-of-the-art MALDI-imaging mass spectroscopy to define the early and late biosignatures of cardiac ECM remodeling post-MI and determine the impact of CD39 on ECM remodeling. The outcomes of these studies will reveal the fundamental pathways by which CD39 regulates post-MI myocardial repair and could allow novel therapeutic approaches not only to treat fibrotic disorders of the heart, but also of the skin, lungs, bone marrow, liver, or kidneys, thereby providing an important translational impact.
美国每年有超过100万人患有心肌梗死(MI)。心肌 心肌梗死(MI)引起强烈的炎症反应。旁分泌和自分泌释放细胞外ATP 通过嘌呤能P2受体(P2 X和P2 Y)进行信号传导的eATP是巨噬细胞的有效调节剂, 成纤维细胞功能细胞外ATP被跨膜蛋白Ectonucleoside triphosphate水解 二磷酸水解酶1(CD 39)产生腺苷一磷酸(AMP),从而阻止促炎性 ATP介导的信号传导。该项目的目标是确定巨噬细胞和成纤维细胞的作用- 在MI后心脏修复中表达CD 39。为实现这一目标,我们提出以下建议:目标1: 确定CD 39上调是否是限制自分泌ATP驱动的 炎症,防止过度的巨噬细胞反应,并保护心肌梗死后纤维化, 将:1)确定CD 39活性如何影响TLR-4依赖性和IL-4依赖性巨噬细胞功能, 2)确定CD 39活性对体内巨噬细胞表型从 3)确定巨噬细胞CD 39在心肌梗死后修复过程中的作用, 心肌梗死后修复纤维化。目的2:分析CD 39介导的抑制CD 39表达的嘌呤能通路, TGF-β1对心脏成纤维细胞的激活作用及CD 39上调对成纤维细胞的调节作用 功能和调节心肌梗死后的心脏修复,我们将1)确定下游靶点, CD 39减弱TGF-β1介导的心脏成纤维细胞炎症和纤维化反应,2)确定 在心脏修复过程中CD 39对体内心脏成纤维细胞表型的影响,以及3)确定 成纤维细胞CD 39对MI后修复期间体内细胞外基质重塑的影响。次要目的:确定 CD 39表达对细胞外基质重塑的影响,我们将使用最先进的MALDI成像 质谱以确定MI后心脏ECM重塑的早期和晚期生物特征, 确定CD 39对ECM重塑的影响。这些研究的结果将揭示基本的 CD 39调节MI后心肌修复的途径,并可能允许新的治疗方法 不仅用于治疗心脏的纤维变性疾病,而且用于治疗皮肤、肺、骨髓、肝或肾的纤维变性疾病, 从而提供重要的平移影响。

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Estrogenic bias in T-Lymphocyte biology: Implications for cardiovascular disease.
  • DOI:
    10.1016/j.phrs.2021.105606
  • 发表时间:
    2021-08
  • 期刊:
  • 影响因子:
    9.3
  • 作者:
    Rosenzweig R;Gupta S;Kumar V;Gumina RJ;Bansal SS
  • 通讯作者:
    Bansal SS
Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art.
  • DOI:
    10.3389/fcvm.2022.850028
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Al-Abcha A;Radwan Y;Blais D;Mazzaferri EL Jr;Boudoulas KD;Essa EM;Gumina RJ
  • 通讯作者:
    Gumina RJ
Immune cell Dilemma in Ischemic Cardiomyopathy: To Heal or Not to Heal.
  • DOI:
    10.1016/j.cophys.2020.09.002
  • 发表时间:
    2021-03
  • 期刊:
  • 影响因子:
    2.5
  • 作者:
    Nehra S;Gumina RJ;Bansal SS
  • 通讯作者:
    Bansal SS
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.
  • DOI:
    10.1126/scitranslmed.abn8057
  • 发表时间:
    2022-03-23
  • 期刊:
  • 影响因子:
    17.1
  • 作者:
    Evans JP;Zeng C;Carlin C;Lozanski G;Saif LJ;Oltz EM;Gumina RJ;Liu SL
  • 通讯作者:
    Liu SL
Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H.
  • DOI:
    10.1128/mbio.02510-21
  • 发表时间:
    2021-10-26
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    Zeng C;Evans JP;Faraone JN;Qu P;Zheng YM;Saif L;Oltz EM;Lozanski G;Gumina RJ;Liu SL
  • 通讯作者:
    Liu SL
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard J Gumina其他文献

Richard J Gumina的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard J Gumina', 18)}}的其他基金

Influence of T cell genotype/phenotype in atherosclerotic cardiovascular disease
T细胞基因型/表型对动脉粥样硬化性心血管疾病的影响
  • 批准号:
    10754115
  • 财政年份:
    2023
  • 资助金额:
    $ 38.42万
  • 项目类别:
Ectonucleotidases in ischemic heart disease
外切核苷酸酶在缺血性心脏病中的作用
  • 批准号:
    10025031
  • 财政年份:
    2020
  • 资助金额:
    $ 38.42万
  • 项目类别:
Ectonucleotidases in ischemic heart disease
外切核苷酸酶在缺血性心脏病中的作用
  • 批准号:
    9384595
  • 财政年份:
    2017
  • 资助金额:
    $ 38.42万
  • 项目类别:
Ectonucleotidases in ischemic heart disease
外切核苷酸酶在缺血性心脏病中的作用
  • 批准号:
    9922592
  • 财政年份:
    2017
  • 资助金额:
    $ 38.42万
  • 项目类别:
Effect of sarcolemmal KATP channels on ROS/RNS generation and calcium handling
肌膜 KATP 通道对 ROS/RNS 生成和钙处理的影响
  • 批准号:
    8496577
  • 财政年份:
    2009
  • 资助金额:
    $ 38.42万
  • 项目类别:
Effect of sarcolemmal KATP channels on ROS/RNS generation and calcium handling
肌膜 KATP 通道对 ROS/RNS 生成和钙处理的影响
  • 批准号:
    8300120
  • 财政年份:
    2009
  • 资助金额:
    $ 38.42万
  • 项目类别:
CD39-mediated cardiovascular protection
CD39介导的心血管保护
  • 批准号:
    7740404
  • 财政年份:
    2009
  • 资助金额:
    $ 38.42万
  • 项目类别:
Effect of sarcolemmal KATP channels on ROS/RNS generation and calcium handling
肌膜 KATP 通道对 ROS/RNS 生成和钙处理的影响
  • 批准号:
    8116646
  • 财政年份:
    2009
  • 资助金额:
    $ 38.42万
  • 项目类别:
Effect of sarcolemmal KATP channels on ROS/RNS generation and calcium handling
肌膜 KATP 通道对 ROS/RNS 生成和钙处理的影响
  • 批准号:
    7907668
  • 财政年份:
    2009
  • 资助金额:
    $ 38.42万
  • 项目类别:
CD39-mediated cardiovascular protection
CD39介导的心血管保护
  • 批准号:
    7888321
  • 财政年份:
    2009
  • 资助金额:
    $ 38.42万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 38.42万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 38.42万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.42万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.42万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 38.42万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.42万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 38.42万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 38.42万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 38.42万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.42万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了